RATIONALE FOR CANCER TARGET

Programmed death-ligand 1 (PD-L1) functions as an immune checkpoint, regulating anti-tumor T cell responses and is present on both tumor cells and immune cells within the tumor microenvironment across various cancers. Toll-like receptors (TLRs) play a crucial role in bridging innate and adaptive immunity by facilitating T cell priming and activation by innate immune cells. As a result, TLR agonism is a potential mechanism for cancer immunotherapy, though their clinical use is limited due to toxicity.

OVERVIEW

Through targeting PD-L1-expressing immunosuppressive macrophages and dendritic cells within the tumor and associated immune compartments, PF-08046037 aims to repolarize the suppressive tumor microenvironment, enhance antigen presentation, and establish anti-tumor immunity.